Human Trials

Rocket Pharmaceuticals treats first patient in phase 1 trial of RP-L301 for PKD

Rocket Pharmaceuticals said that the first patient has received investigational therapy in the open-label, Phase 1 clinical trial of RP-L301, the Company’s lentiviral vector (LVV)-based gene therapy for the treatment of Pyruvate Kinase Deficiency (PKD), a rare monogenic red blood cell disorder.

Glenmark commences 1000 patients post marketing surveillance study with Covid-19 who are administered FabiFlu

Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, has announced that it has commenced a Post Marketing Surveillance (PMS) study on FabiFlu to closely monitor the efficacy and safety of the drug in 1000 patients that are prescribed with the oral antiviral, as part of an open label, multicenter, single arm study.

Russian university completes human trials of coronavirus vaccine candidate

Russia's Sechenov First Moscow State Medical University (Sechenov University) has reportedly completed clinical trials of a coronavirus vaccine candidate developed by Gamaleya Research Institute of Epidemiology and Microbiology.

Moderna completes enrolment of phase 2 study of its mRNA vaccine against Covid-19

Moderna, a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced that it has completed enrollment for both cohorts of the Phase 2 study of its vaccine candidate (mRNA-1273) against Covid-19.

Corvus begins phase 1 Covid-19 clinical trial with novel immunotherapy

Clinical-stage biopharmaceutical firm Corvus Pharmaceuticals has commenced the phase 1 clinical study of novel Immunotherapy for patients with Covid-19 disease.

VROBIO announces new patients dosed in Gaucher disease and cystinosis trials

AVROBIO announced that the first patient has been dosed in the company’s GuardOne clinical trial, a Phase 1/2 investigational study evaluating AVR-RD-02 for Gaucher disease type 1.

Sunovion’s SEP-4199 fails to meet primary endpoint in SEP380-201 trial

Sunovion Pharmaceuticals said that a phase 2 study evaluating SEP-4199 as the treatment of major depressive episodes associated with bipolar I disorder (bipolar I depression) failed to meet its primary endpoint.

Sinovac Covid-19 vaccine collaboration with Butantan receives approval from Brazilian regulator for phase III trial

Sinovac Biotech ( “Sinovac” or the “ Company”)(Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced an update to its previously announced partnership with Butantan, a leading Brazilian producer of immunobiologic products and vaccines.

Regeneron begins Phase 3 trial of Covid-19 ‘antibody cocktail’ drug

Regeneron Pharmaceuticals has announced the commencement of Phase 3 trial with its investigational double-antibody cocktail REGN-COV2 to treat and prevent Covid-19 disease.